DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 202288
NDA 202288 describes LITHIUM CARBONATE, which is a drug marketed by Able, Alembic Ltd, Apotex Inc, Glenmark Generics, Hetero Labs Ltd Iii, Mylan Pharms Inc, Usl Pharma, Watson Labs, West-ward Pharms Int, Alembic Pharms Ltd, Barr, Glenmark Pharms Inc, Heritage Pharma, Hikma Intl Pharms, Unique Pharm Labs, Pfizer, and Sun Pharm Inds Inc, and is included in twenty-nine NDAs. It is available from twenty-nine suppliers. Additional details are available on the LITHIUM CARBONATE profile page.
The generic ingredient in LITHIUM CARBONATE is lithium carbonate. There are fifteen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
The generic ingredient in LITHIUM CARBONATE is lithium carbonate. There are fifteen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
Summary for 202288
| Tradename: | LITHIUM CARBONATE |
| Applicant: | Mylan Pharms Inc |
| Ingredient: | lithium carbonate |
| Patents: | 0 |
| Therapeutic Class: | Bipolar Agents |
| Formulation / Manufacturing: | see details |
Suppliers and Packaging for NDA: 202288
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LITHIUM CARBONATE | lithium carbonate | TABLET, EXTENDED RELEASE;ORAL | 202288 | ANDA | Mylan Pharmaceuticals Inc. | 0378-1300 | N | 0378-1300-05 |
| LITHIUM CARBONATE | lithium carbonate | TABLET, EXTENDED RELEASE;ORAL | 202288 | ANDA | Mylan Pharmaceuticals Inc. | 0378-1300 | N | 0378-1300-01 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 300MG | ||||
| Approval Date: | Jun 29, 2012 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
